HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment.

AbstractAIM:
The genetic origin of familial combined hyperlipidemia (FCH) is not well understood. We used microarray profiling of peripheral blood monocytes to search novel genes and pathways involved in FCH.
METHODS:
Fasting plasma for determination of lipid profiles, inflammatory molecules and adipokines was obtained and peripheral blood monocytes were isolated from male FCH patients basally and after 4 weeks of atorvastatin treatment. Sex-, age- and adiposity-matched controls were also studied. Gene-expression profiles were analyzed using Affymetrix Human Genome U133A 2.0 GeneChip arrays.
RESULTS:
Analysis of gene expression by cDNA microarrays showed that 82 genes were differentially expressed in FCH monocytes compared with controls. Atorvastatin treatment modified the expression of 86 genes. Pathway analysis revealed the over-representation of the complement and coagulation cascades, the hematopoietic cell lineage and the arachidonic acid metabolism pathways. Changes in the expression of some genes, confirmed by real-time RT-PCR, (CD36, leucine-rich repeats and immunoglobulin-like domains-1, tissue factor pathway inhibitor 2, myeloid cell nuclear differentiation antigen, tumor necrosis factor receptor superfamily, member 25, CD96 and lipoprotein lipase), may be related to a proinflammatory environment in FCH monocytes, which is partially reversed by atorvastatin. Higher plasma levels of triglycerides and free fatty acids and lower levels of adiponectin in FCH patients could also trigger changes in gene expression that atorvastatin cannot modify.
CONCLUSION:
Our results show clear differences in gene expression in FCH monocytes compared with those of matched healthy controls, some of which are influenced by atorvastatin treatment.
AuthorsGemma Llaverias, Jordi Pou, Emilio Ros, Daniel Zambón, Montserrat Cofán, Alex Sánchez, Manuel Vázquez-Carrera, Rosa M Sánchez, Juan C Laguna, Marta Alegret
JournalPharmacogenomics (Pharmacogenomics) Vol. 9 Issue 8 Pg. 1035-54 (Aug 2008) ISSN: 1744-8042 [Electronic] England
PMID18681780 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Heptanoic Acids
  • Inflammation Mediators
  • Pyrroles
  • Atorvastatin
Topics
  • Aged
  • Atorvastatin
  • Gene Expression Profiling (methods)
  • Heptanoic Acids (pharmacology, therapeutic use)
  • Humans
  • Hyperlipidemia, Familial Combined (drug therapy, genetics, metabolism, pathology)
  • Inflammation Mediators (pharmacology, therapeutic use)
  • Male
  • Middle Aged
  • Monocytes (drug effects, pathology, physiology)
  • Pyrroles (pharmacology, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: